Brazilian pharmaceutical company Brazil learns about achievements of Cuban scientific center

Havana, April 27 (RHC) - A delegation representing the Brazilian company MRJ Farma visited the Cuban Center for Genetic Engineering and Biotechnology (CIGB) on Thursday, where they received details about the achievements of that scientific institution.

The CIGB is a distinguished place of science, with great results and thousands of positive ratings. Founded in 1986 by Fidel Castro, historical leader of the Cuban Revolution, the CIGB is a significant part of the scientific history of Cuba and the world for the development of various drugs and vaccines, such as two of the five Cuban immunogens against Covid-19: Mambisa and Abdala.

Abdala, the first vaccine conceived in Latin America, demonstrated 92.28 percent efficacy in its phase III clinical trial and millions of doses have already been administered in the Caribbean nation and in others such as Venezuela, Nicaragua, the Sahrawi Arab Democratic Republic and Vietnam.

The Mambisa vaccine candidate, for its part, is placed among the immunogens designed globally to be administered nasally and thus attack the main entry of the SARS-CoV-2 coronavirus, which causes the Covid-19 pandemic.

The CIGB also works on other topics and technological platforms, including recombinant proteins, chemical synthesis and synthetic peptides.

Gerardo Guillén, director of biomedical research at that center, explained that protein printing is being done in different hosts, such as yeast, mammalian cells, and bacteria. They also investigate other diagnostic platforms, vaccines and therapeutic solutions.

Among CIGB’s most recognized products is Heberferon, consisting of a mixture of alpha and gamma interferons but contained in a single vial with synergistic properties based on its antiproliferative activity.

The Brazilian company MRJ Farma produces more than 35 products in the areas of nutrition and vitamin supplements, among others. (Sources: Prensa Latina)